Table 2.

Parameter values for the model development

Variable name coded in R	Value	Description
Costs
cPFS	500	State cost of one cycle in the progression-free disease state
cPD	3000	State cost of one cycle in the progressive disease state
cDrug	1000	State cost of drug for one cycle
cTest	100	State cost of biomarker testing for one cycle
cDead	0	State cost of one cycle in the death
Quality-of-life adjustments
uPFS.UC	0.75	Quality-of-life weight for one cycle in PFS for patients treated with usual care
uPD.UC	0.65	Quality-of-life weight for one cycle in PD for patients treated with usual care
uPFS.TC	0.80	Quality-of-life weight for one cycle in PFS for patients treated with targeted care
uPD.TC	0.70	Quality-of-life weight for one cycle in PD for patients treated with targeted care
Biomarker-related parameters
disutility.Test	0.05	Disutility value of testing a biomarker status
pBiomarker	0.74	Biomarker prevalence/frequency
tp	0.285	Biomarker testing accuracy (true positive)
fp	0.245	Biomarker testing accuracy (false positive)
tn	0.015	Biomarker testing accuracy (true negative)
fn	0.455	Biomarker testing accuracy (false negative)
Transition probabilities
pPFS2PD	0.2	Probability of entering the PD state
pPD2D	0.25	Probability of dying from PD
pPFS2D	0.05	Probability of dying from PFS
pPD2PFS	0	Recovery from PD to PFS is not permitted in the model
Other parameters
eff	0.25	Targeted drug reduces the likelihood of being progressed by 25% Relative risk of disease progression from using the drug Targeted drug is discontinued upon progression
rDiscount	0.035	Discount rate for outcomes and costs 3.5%

PFS progression-free survival, PD progressed disease